Research I 04 February 2026 OECD cites EuroACT data in the new report on High Value Cancer Care We are proud to share that the Organisation for Economic Co-operation and Development (OECD-OCDE) has published its 2026 report Delivering Hight Value Cancer Care, and EuroACT data has played a key role in shaping it. The report can be accessed here: https://lnkd.in/eRsupumz EuroACT insights
Research I 03 November 2025 Our haematological diseases preprint is now available on Preprints with The Lancet! Read it here: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5646744 Title: Variation in Use of Patient-Reported Outcome Measures and in Geographical Distribution in Clinical Trials of Selected Malignant and Non-Malignant Haematological Diseases in Europe: Findings from EuroACT This study analysed data
Research I 20 October 2025 Best Poster Award at ESMO 2025! The EuroACT project was featured Sunday 19th October 2025 at ESMO 2025 Congress showcasing our work on mapping the European clinical trial landscape. We are proud to share that our poster received the Best Poster Award, recognising its outstanding clarity of
Research I 14 October 2025 Novel EuroACT methodology just published! We are proud to share EuroACT’s new article: “Methodological study protocol for The European Atlas of Clinical Trials in Cancer and Haematology.” This peer-reviewed paper, developed and reviewed by scientific experts, confirms the robustness of the Atlas approach. The Atlas will: Map
Research I 10 September 2025 Our Solid Tumours preprint is now available online We are thrilled to share a big milestone for EuroACT! Our Solid Tumours preprint is now available online: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5390471 This study analysed 20,658 clinical trials across 12 tumour types in Europe, uncovering substantial geographic inequities in the use of Patient-Reported
Research I 18 August 2025 Recognition for EuroACT: Collaborating with OECD on European Health Policy We are pleased to share that the Organisation for Economic Co-operation and Development (OECD) contacted us after discovering our European Atlas on Clinical Trials in Cancer and Hematology (EuroACT) work on our website. This marks an exciting
Research I 6 August 2025 EuroACT Phase 3: Advancing from data to evidence EuroACT Phase 3: Conversion – Data becomes evidence is well underway! This phase builds on the foundations of Phases 1 and 2, focusing on interpreting and iterating our findings to formulate evidence-based messages and impactful advocacy points for the
Research I 7 March 2025 Advancing Research & Patient Advocacy with a Novel Methodology To generate knowledge, we had to create our own tools, and we hope they are useful for advocacy in other areas too! In collaboration with Syreon, we are proud to be pioneers in developing a novel methodology for
Research I 11 June 2023 Research questions of phase 2 established Where are we at? Research questions have been drafted by the steering committee and have been reviewed and entire oncology and hematological community ensuring that the data outcomes are suited to their needs and answer questions they have around the three main
Research I 11 June 2023 Phase 2 kick off Phase 1 completing and now moving to Phase 2 - analysis nd of phase 1 resulted in the collection of all interventional studies (phase 2,3 or 4) in each disease area. Obtaining the data from either the clinical trial registry, ClinialTrials.gov or EU Clinical